189 related articles for article (PubMed ID: 8086134)
1. Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity.
Stretcher BN; Pesce AJ; Frame PT; Greenberg KA; Stein DS
AIDS; 1994 Jun; 8(6):763-9. PubMed ID: 8086134
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylated zidovudine concentrations in mononuclear cells in pediatric patients with human immunodeficiency virus infections.
Wintermeyer SM; Nahata MC; Brady MT; Sobol BJ; Venglarcik JS 3rd ; Baker RC; Hunkler JA; McOwen NM
Pediatr AIDS HIV Infect; 1997 Apr; 8(2):120-6. PubMed ID: 11361778
[TBL] [Abstract][Full Text] [Related]
3. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine.
Jacobson MA; Bacchetti P; Kolokathis A; Chaisson RE; Szabo S; Polsky B; Valainis GT; Mildvan D; Abrams D; Wilber J
BMJ; 1991 Jan; 302(6768):73-8. PubMed ID: 1671651
[TBL] [Abstract][Full Text] [Related]
4. A comparison of two dosing regimens of zidovudine in Thai adults with early symptomatic HIV infection. Conducting clinical HIV trials in South-East Asia.
Phanuphak P; Grayson ML; Sirivichayakul S; Suwanagool S; Ruxrungtham K; Hanvanich M; Ratanasuwan W; Ubolyam S; Hughes MD; Wanke CA; Hammer SM
Aust N Z J Med; 2000 Feb; 30(1):11-20. PubMed ID: 10800872
[TBL] [Abstract][Full Text] [Related]
5. Zidovudine plus interferon-alpha versus zidovudine alone in HIV-infected symptomatic or asymptomatic persons with CD4+ cell counts > 150 x 10(6)/L: results of the Zidon trial. Zidon Study Group.
Fernández-Cruz E; Lang JM; Frissen J; Furner V; Châteauvert M; Boucher CA; Dowd P; Stevens J
AIDS; 1995 Sep; 9(9):1025-35. PubMed ID: 8527074
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus.
Stretcher BN; Pesce AJ; Frame PT; Stein DS
Antimicrob Agents Chemother; 1994 Jul; 38(7):1541-7. PubMed ID: 7979286
[TBL] [Abstract][Full Text] [Related]
7. Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection.
Godfried MH; van der Poll T; Mulder JW; Weverling GJ; Endert E; Lange JM; Sauerwein HP
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec; 10(5):531-9. PubMed ID: 8548332
[TBL] [Abstract][Full Text] [Related]
8. Predictive value for survival of soluble tumor necrosis factor receptors p55 and p75 during zidovudine-containing treatment in symptomatic human immunodeficiency virus type 1 infection.
Frissen PH; Weverling GJ; Endert E; Jansen J; Sauerwein HP; Lange JM
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Aug; 12(5):482-8. PubMed ID: 8757425
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic evaluation of the effects of ribavirin on zidovudine triphosphate formation: ACTG 5092s Study Team.
Aweeka FT; Kang M; Yu JY; Lizak P; Alston B; Chung RT;
HIV Med; 2007 Jul; 8(5):288-94. PubMed ID: 17561874
[TBL] [Abstract][Full Text] [Related]
10. Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group.
Phillips AN; Eron J; Bartlett J; Kuritzkes DR; Johnson VA; Gilbert C; Johnson J; Keller A; Hill AM
AIDS; 1997 Feb; 11(2):169-75. PubMed ID: 9030363
[TBL] [Abstract][Full Text] [Related]
11. Elevated serum calprotectin levels in HIV-infected patients: the calprotectin response during ZDV treatment is associated with clinical events.
Müller F; Frøland SS; Aukrust P; Fagerhol MK
J Acquir Immune Defic Syndr (1988); 1994 Sep; 7(9):931-9. PubMed ID: 7914232
[TBL] [Abstract][Full Text] [Related]
12. Effect of antiretroviral therapy on the cerebrospinal fluid of patients seropositive for the human immunodeficiency virus.
Gulevich SJ; McCutchan JA; Thal LJ; Kirson D; Durand D; Wallace M; Mehta P; Heyes MP; Grant I
J Acquir Immune Defic Syndr (1988); 1993 Sep; 6(9):1002-7. PubMed ID: 8101873
[TBL] [Abstract][Full Text] [Related]
13. Zidovudine phosphorylation in HIV-infected patients and seronegative volunteers.
Barry M; Wild M; Veal G; Back D; Breckenridge A; Fox R; Beeching N; Nye F; Carey P; Timmins D
AIDS; 1994 Aug; 8(8):F1-5. PubMed ID: 7986398
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of soluble CD8, neopterin, beta 2-microglobulin and p24 antigen as indicators of disease progression in children with AIDS on zidovudine therapy.
Siller L; Martin NL; Kostuchenko P; Beckett L; Rautonen J; Cheng SC; Wara DW
AIDS; 1993 Mar; 7(3):369-73. PubMed ID: 8097095
[TBL] [Abstract][Full Text] [Related]
15. The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites.
Barry MG; Khoo SH; Veal GJ; Hoggard PG; Gibbons SE; Wilkins EG; Williams O; Breckenridge AM; Back DJ
AIDS; 1996 Oct; 10(12):1361-7. PubMed ID: 8902065
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with recombinant human soluble CD4-immunoglobulin G and zidovudine in patients with HIV infection: a phase I study.
Meng TC; Fischl MA; Cheeseman SH; Spector SA; Resnick L; Boota A; Petrakis T; Wright B; Richman DD
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Feb; 8(2):152-60. PubMed ID: 7834398
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic variability of zidovudine in HIV-infected individuals: subgroup analysis and drug interactions.
Burger DM; Meenhorst PL; ten Napel CH; Mulder JW; Neef C; Koks CH; Bult A; Beijnen JH
AIDS; 1994 Dec; 8(12):1683-9. PubMed ID: 7888117
[TBL] [Abstract][Full Text] [Related]
18. Concentrations of phosphorylated zidovudine (ZDV) in patient leukocytes do not correlate with ZDV dose or plasma concentrations.
Stretcher BN; Pesce AJ; Murray JA; Hurtubise PE; Vine WH; Frame PT
Ther Drug Monit; 1991 Jul; 13(4):325-31. PubMed ID: 1780965
[TBL] [Abstract][Full Text] [Related]
19. Quantification of HIV-1 virus load under zidovudine therapy in patients with symptomatic HIV infection: relation to disease progression.
Molina JM; Ferchal F; Chevret S; Barateau V; Poirot C; Morinet F; Modai J
AIDS; 1994 Jan; 8(1):27-33. PubMed ID: 7912084
[TBL] [Abstract][Full Text] [Related]
20. An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine.
Foudraine NA; de Jong JJ; Jan Weverling G; van Benthem BH; Maas J; Keet IP; Jurriaans S; Roos MT; Vandermeulen K; de Wolf F; Lange JM
AIDS; 1998 Aug; 12(12):1513-9. PubMed ID: 9727573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
